Los Angeles Times Examines Problems With Pharmaceutical Industry Focus On 'Blockbuster' Medications
Pharmaceutical companies for 25 years have "imitated the basic business model of Hollywood" and have "focused on creating blockbusters," which they "hope will appeal to masses" and "promote like mad," according to the Times. Pharmaceutical companies must spend as much as $1 billion to promote new medications in their first two years on the market to make the products into a "mega-brand" with at least $1 billion in annual sales.
"Only now is it becoming clear that this business model couldn't work forever," as the strategy "had a flaw that executives have long ignored" -- the approach "required extraordinary amounts of promotion at the expense of scientific creativity," the Times reports. During the next several years, pharmaceutical companies will lose patent protection on a number of popular and profitable medications -- such as the osteoporosis treatment Fosamax, manufactured by Merck, the antipsychotic Risperdal, manufactured by Johnson & Johnson, and the cholesterol medication Lipitor, manufactured by Pfizer -- and the "industry's scientists have hit a dry spell" and are "not discovering enough new drugs to replace the aging standbys," the Times reports.
"It would be wrong to believe that this is the end of the industry's wealth and power," but, as some pharmaceutical companies "struggle, patients will bear the brunt," with the prices of medications likely to "rise even faster," according to the Times (Petersen, Los Angeles Times, 1/27).
Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
View drug information on Fosamax; Risperdal Oral Formulation.
Los Angeles Times analizeazã problemele cu industria farmaceuticã se concentreze pe 'Blockbuster' medicaþiei - Los Angeles Times Examines Problems With Pharmaceutical Industry Focus On 'Blockbuster' Medications - articole medicale engleza - startsanatate